Market move - Summit Therapeutics PLC (NASDAQ:SMMT) shares rose 5.8% in premarket trading Wednesday following a change in analyst stance from Jefferies. The investment bank moved the stock from Hold to Buy and lifted its price target to $25 from $15.
Analyst rationale - Faisal Khurshid of Jefferies highlighted the company’s upcoming H3 progression-free survival (PFS) readout, expected in late 2026, as the primary catalyst behind the upgrade. According to the analyst, the firm’s review of the statistical plans and comparisons between China and the broader global trial population indicates that the PFS result is likely to achieve statistical significance, provided there is no outlier degradation when bridging data from China to the global cohort.
Jefferies’ modeling points to a progression-free survival hazard ratio in the range of 0.65-0.70 as the most likely outcome. Under those assumptions, the analyst suggests a downstream overall survival (OS) advantage could be realized as early as the first half of 2027. The analysis further notes that even a PFS hazard ratio below 0.75 would still be treated as a favorable result.
Program confidence - Khurshid also emphasized Jefferies' confidence in the underlying mechanism of action for ivonescimab, citing prior positive overall survival findings in the H6, H2 and H-GI1 trials. The analyst described ivonescimab as a first-in-class therapy, which Jefferies believes should support the asset’s value if the trial readouts align with expectations.
Company profile - Summit Therapeutics is a biopharmaceutical company focused on developing new medicines aimed at patients with unmet medical needs. The Jefferies upgrade and target increase reflect the brokerage’s view on the clinical program’s potential impact on shareholder value.
What to watch - Market participants will be watching the H3 progression-free survival data due in late 2026 and any signals about how China-based results compare with the global trial population. Those comparisons are central to Jefferies’ assessment of statistical significance and to its projection of a potential overall survival benefit in early 2027.
Note: The article reports on the analyst upgrade, projected trial timelines and modeled hazard ratios as described by Jefferies. It does not add or infer any outcomes beyond the statements and figures provided by the analyst.